• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

byJake EngelandMichael Pratte
February 9, 2022
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This randomized controlled trial demonstrated that in adult type 2 diabetes patients on daily basal insulin, adding tirzepatide significantly reduced HbA1C and improved weight loss at 40 weeks compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Basal insulin is used in type 2 diabetic patients with poor glycemic control despite oral hypoglycemics. Increasing the dose of basal insulin can reduce blood glucose levels, however, this also increases the risk of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists can improve glucose control and weight gain without increasing the risk of hypoglycemia. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. The SURPASS-5 randomized, double-blind, placebo-controlled trial investigated whether tirzepatide added to basal insulin improves glycemic control in type 2 diabetes (T2D) patients. Participants with T2D, baseline HbA1C of 7.0%-10.5%, and on daily basal insulin were randomized to receive a 1:1:1:1 ratio of 5 mg, 10 mg, 15 mg tirzepatide, or placebo between August 30, 2019, and March 20, 2020; participants were followed for 40 weeks and received weekly subcutaneous injections of tirzepatide or placebo. The primary outcome was the mean change from baseline HbA1C at 40 weeks. Safety outcomes were assessed after 4 weeks. There were significant reductions in HbA1C at 40 weeks in all treatment groups compared to placebo (5 mg: difference vs. placebo [DVP], -1.24 [95% CI: -1.48 to -1.01], p<0.001. 10 mg: DVP, -1.53 [95% CI: -1.77 to -1.30], p<0.001. 15 mg: DVP, -1.47 [95% CI: -1.71 to -1.23], p<0.001). Additionally, bodyweight was significantly reduced in all three treatment groups compared to placebo (5 mg: DVP, -7.1 kg [95% CI: -8.7 to -5.4], p<0.001. 10 mg: DVP, -9.1 kg [95% CI: -10.7 to -7.5], p<0.001. 15 mg: DVP, -10.5 kg [95% CI: -12.1 to -8.8], p<0.001). Serious adverse events occurred in 7.8%-10.9% of participants in the treatment groups compared to 8.3% of patients in the placebo group. Hypoglycemia occurred in 14.2%-19.3% in the tirzepatide groups versus 12.5% of participants in the placebo cohort. Overall, supplementation of weekly tirzepatide on top of daily basal insulin significantly improved glycemic control and weight loss after 40 weeks in T2D patients. One limitation of this study, however, is that participants in this study were using basal insulin glargine with or without metformin, so these outcomes may not be generalizable to other oral hypoglycemic treatment regimens for T2D.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Image: PD

RELATED REPORTS

Faricimab may improve visual acuity in patients with diabetic macular edema

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

Prevalence of diabetes mellitus in China, 2013-2018

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetes mellitusTirzepatideType 2 Diabetes Mellitus
Previous Post

Nivolumab combination therapies improved overall survival in patients with advanced esophageal squamous cell carcinoma

Next Post

Neonatal deaths in premature infants correlate with gestational age at birth

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Cardiology

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

January 11, 2022
Food environment associated with gestational diabetes
Chronic Disease

Prevalence of diabetes mellitus in China, 2013-2018

December 29, 2021
#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes
StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

December 2, 2021
Next Post
Children born late preterm birth at higher odds to fail standardized tests

Neonatal deaths in premature infants correlate with gestational age at birth

Increased risk of stillbirth recurrence after a previous stillbirth

Wellness Check: Spirituality

Gastric bypass surgery reduces cardio-metabolic risk factors

Significant morbidity among children observed following reintroduction of high-powered magnets into US market

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
  • Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer
  • Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.